 Home > Medical News > Medical World News > Innovative first-line therapy for gastric cancer is recognized by FDA as breakthrough therapy

Innovative first-line therapy for gastric cancer is recognized by FDA as breakthrough therapy

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

photothermal therapy

requip drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Amgen announced that the US FDA has granted its research FGFR2b antibody therapy bemarituzumab breakthrough therapy designation, combined with chemotherapy, for the first-line treatment of HER2-negative locally advanced or metastatic gastric cancer and gastroesophageal junction (GEJ ) Cancer patients.

More than 1 million new gastric cancer patients are diagnosed each year, and its incidence is particularly high in Asia.

Bemarituzumab is a monoclonal antibody against FGFR2b.

▲The mechanism of action of bemarituzumab (picture source: Five Prime official website)

The award of this breakthrough therapy designation is based on the positive results of the Phase 2 clinical trial FIGHt.

"FIGHT clinical trial is the first study to evaluate targeted FGFR2b overexpression in cancer.

Reference materials:

[1] Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Amgen's innovative first-line therapy for gastric cancer, bemarituzumab, is recognized by the U.S. FDA as a breakthrough therapy

05-08

Related Products

36070-75-4

CAS No.: 36070-75-4

$1-1.1/MT FOB

USA/AU/EU warehouse supply high quality 2-Picolinic acid powder CAS 98-98-6 and 2-Picolinic acid

CAS No.: 98-98-6

Pharmacy Grade

$10-13/KG FOB

4-Nitro-2,3-lutidine-N-oxide

CAS No.: 37699-43-7

Industrial Grade / pharmaceutical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Innovative first-line therapy for gastric cancer is recognized by FDA as breakthrough therapy

Related Articles

Amgen's innovative first-line therapy for gastric cancer, bemarituzumab, is recognized by the U.S. FDA as a breakthrough therapy